Center for Cancer Targeted Therapies Archives
Balko lands Mary Kay Foundation grant for breast cancer research
Dec. 5, 2019—Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.
Study seeks to boost breast tumor immune response
Feb. 8, 2018—Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer.
Investigators match novel cancer mutations with potential therapies
Aug. 3, 2017—Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.
Arteaga to direct UT Southwestern cancer center
Jul. 13, 2017—Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.
VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’
Dec. 10, 2015—Justin Balko, Pharm.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been named a member of the 2016 class of Pink Tie Guys by the Greater Nashville Affiliate of Susan G. Komen, a nonprofit organization dedicated to breast cancer research and patient support.
VICC debuts new Center for Cancer Targeted Therapies
Oct. 31, 2013—Vanderbilt-Ingram Cancer Center leaders formally dedicated the space for the new Center for Cancer Targeted Therapies (CCTT), located in the Infusion Center on the second floor of The Vanderbilt Clinic, at a special ribbon-cutting held during last week’s fall meeting of the Cancer Center’s Board of Overseers.
